NO20066050L - Substituerte indazoler, sammensetninger inneholdende disse samt fremstilling og anvendelse derav - Google Patents

Substituerte indazoler, sammensetninger inneholdende disse samt fremstilling og anvendelse derav

Info

Publication number
NO20066050L
NO20066050L NO20066050A NO20066050A NO20066050L NO 20066050 L NO20066050 L NO 20066050L NO 20066050 A NO20066050 A NO 20066050A NO 20066050 A NO20066050 A NO 20066050A NO 20066050 L NO20066050 L NO 20066050L
Authority
NO
Norway
Prior art keywords
preparation
compositions containing
substituted indazoles
indazoles
substituted
Prior art date
Application number
NO20066050A
Other languages
English (en)
Norwegian (no)
Inventor
Herve Bouchard
Michel Tabart
Fabrice Viviani
Odile Angouillant-Boniface
Franck Halley
Catherine Souaille
Alain Le Brun
Laurence Gauzy-Lazo
Pascal Desmazeau
Bruno Filoche-Romme
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34946329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20066050(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20066050L publication Critical patent/NO20066050L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20066050A 2004-06-04 2006-12-28 Substituerte indazoler, sammensetninger inneholdende disse samt fremstilling og anvendelse derav NO20066050L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0406042A FR2871158A1 (fr) 2004-06-04 2004-06-04 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
PCT/FR2005/001335 WO2006003276A1 (fr) 2004-06-04 2005-06-01 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
NO20066050L true NO20066050L (no) 2007-02-05

Family

ID=34946329

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20066050A NO20066050L (no) 2004-06-04 2006-12-28 Substituerte indazoler, sammensetninger inneholdende disse samt fremstilling og anvendelse derav

Country Status (22)

Country Link
US (1) US7517902B2 (zh)
EP (1) EP1765813A1 (zh)
JP (1) JP2008501669A (zh)
KR (1) KR20070043769A (zh)
CN (1) CN1980918A (zh)
AR (1) AR049389A1 (zh)
AU (1) AU2005259139B2 (zh)
BR (1) BRPI0510777A (zh)
CA (1) CA2567744A1 (zh)
CR (1) CR8767A (zh)
EA (1) EA012702B1 (zh)
EC (1) ECSP067046A (zh)
FR (1) FR2871158A1 (zh)
IL (1) IL179595A0 (zh)
MA (1) MA28664B1 (zh)
MX (1) MXPA06013954A (zh)
NO (1) NO20066050L (zh)
TN (1) TNSN06384A1 (zh)
TW (1) TW200610756A (zh)
UY (1) UY28941A1 (zh)
WO (1) WO2006003276A1 (zh)
ZA (1) ZA200610040B (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE102006005179A1 (de) * 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
MX2009006401A (es) * 2006-12-20 2009-06-23 Nerviano Medical Sciences Srl Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
KR101636312B1 (ko) 2007-07-20 2016-07-05 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서 활성인 치환된 인다졸 유도체
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
KR20130006664A (ko) * 2010-03-16 2013-01-17 다나-파버 캔서 인스티튜트 인크. 인다졸 화합물 및 그의 용도
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
KR20130077390A (ko) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2016089760A1 (en) 2014-12-02 2016-06-09 Ignyta, Inc. Combinations for the treatment of neuroblastoma
WO2016096709A1 (en) 2014-12-16 2016-06-23 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN106032359B (zh) * 2015-03-09 2018-07-20 复旦大学 吲唑类化合物及其制备方法和用途
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CA3033249A1 (en) 2016-09-23 2018-03-29 Novartis Ag Indazole compounds for use in tendon and/or ligament injuries
CA3050770C (en) * 2016-12-07 2023-09-12 Nanjing Xin Shi Dai Meditech Co. Ltd. Compounds and pharmaceutical compositions for modulating sgk activity, and methods thereof
KR20200031115A (ko) 2017-07-19 2020-03-23 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
US11548867B2 (en) 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
CN109134451A (zh) * 2018-09-10 2019-01-04 遵义医学院 1,3-二取代脲类与硫脲类衍生物及其应用
US20220388964A1 (en) * 2019-04-12 2022-12-08 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
CN114276297A (zh) * 2020-10-15 2022-04-05 兰州大学 一种1h-吲唑vegfr-2激酶抑制剂及其制备与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2971842A (en) * 1956-03-21 1961-02-14 Gen Aniline & Film Corp Light sensitive layers for photomechanical reproduction
KR20020063854A (ko) 1999-09-17 2002-08-05 애보트 게엠베하 운트 콤파니 카게 치료제로서의 키나제 억제제
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
FR2827861B1 (fr) * 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003051847A1 (en) * 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
MXPA04011417A (es) * 2002-05-17 2005-02-14 Pharmacia Italia Spa Derivados de aminoindazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
CA2495216A1 (en) 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
RU2378259C2 (ru) * 2002-09-05 2010-01-10 Авентис Фарма С.А. Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции
PL376789A1 (pl) * 2002-12-12 2006-01-09 Aventis Pharma S.A. Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
DK1638941T3 (da) * 2003-05-22 2010-10-11 Abbott Lab Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
BRPI0608252A2 (pt) 2005-03-10 2010-04-06 Cgi Pharmaceuticals Inc entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas

Also Published As

Publication number Publication date
ECSP067046A (es) 2006-12-29
KR20070043769A (ko) 2007-04-25
EA200602241A1 (ru) 2007-04-27
AR049389A1 (es) 2006-07-26
CA2567744A1 (fr) 2006-01-12
TW200610756A (en) 2006-04-01
EA012702B1 (ru) 2009-12-30
US7517902B2 (en) 2009-04-14
AU2005259139A1 (en) 2006-01-12
AU2005259139B2 (en) 2011-09-08
WO2006003276A1 (fr) 2006-01-12
FR2871158A1 (fr) 2005-12-09
JP2008501669A (ja) 2008-01-24
MXPA06013954A (es) 2007-03-15
EP1765813A1 (fr) 2007-03-28
UY28941A1 (es) 2005-12-30
CR8767A (es) 2007-08-28
MA28664B1 (fr) 2007-06-01
BRPI0510777A (pt) 2007-11-20
TNSN06384A1 (fr) 2008-02-22
ZA200610040B (en) 2008-02-27
US20070161626A1 (en) 2007-07-12
CN1980918A (zh) 2007-06-13
IL179595A0 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
NO20066050L (no) Substituerte indazoler, sammensetninger inneholdende disse samt fremstilling og anvendelse derav
NO20044261L (no) Indazoler substituerte med en anticanceros aktivitet
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
AP2139A (en) 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
TW200801008A (en) Protein kinase inhibitors
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
JO3134B1 (ar) مثبطات نشاط akt
NO20082191L (no) Forbindelser
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
DK1928840T3 (da) 1H-pyrazol-4-carboxamider, deres fremstilling og deres anvendelse som 11-beta-hydroxysteroid-dehydrogenaseinhibitorer
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
NO20075918L (no) Substituerte pyrrolo-pyridiner, forbindelser inneholdende disse, fremgangsmate for deres fremstilling og anvendelse derav
NO20081952L (no) Substituerte pyrazolforbindelser
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20084712L (no) Nye farmasoytiske forbindelser
NO20075275L (no) Nye forbindelser
NO20073033L (no) Cytotoksiske midler innbefattende nye taksaner
ATE552834T1 (de) Zubereitung von 1,6-disubstituierten azabenzimidazolen als kinasehemmer
ATE509933T1 (de) Pentacyclische kinaseinhibitoren
NO20045025L (no) Nye forbindelser
WO2007076320A3 (en) Compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application